Nationwide Evaluation of Robotic Distal Pancreatectomy for Malignancy: Safety, Outcomes, and Comparative Effectiveness in Japan
Posted inGeneral Surgery news Oncology

Nationwide Evaluation of Robotic Distal Pancreatectomy for Malignancy: Safety, Outcomes, and Comparative Effectiveness in Japan

This study analyzes nationwide data from Japan comparing robotic, laparoscopic, and open distal pancreatectomy for malignancy, highlighting robotic surgery’s safety and specific perioperative advantages, notably reduced blood loss and conversion rates, though benefits over laparoscopy remain limited.
New EHR-Based Model PRIME Achieves 0.75 AUC in Predicting Pancreatic Cancer Risk Across 11 Million Patients
Posted inGastroenterology Hematology-Oncology news

New EHR-Based Model PRIME Achieves 0.75 AUC in Predicting Pancreatic Cancer Risk Across 11 Million Patients

Researchers developed PRIME, a parsimonious risk stratification model for pancreatic ductal adenocarcinoma using electronic health record data. Validated across US health systems and the UK Biobank, PRIME retained 19 predictors and achieved strong discrimination, enabling targeted early detection in high-risk populations.
PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial
Posted inGastroenterology news Oncology

PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial

The Phase 3 CASSANDRA trial reveals that the four-drug PAXG regimen significantly improves event-free survival compared to mFOLFIRINOX in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, potentially redefining neoadjuvant standards for this aggressive malignancy.